

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/937,057	02/26/2002	Antoine F Carpentier	249326USOX PCT	4658
22850	7590 06/28/2006		EXAMINER	
	PIVAK, MCCLELLA	ZARA, JANE J		
	KE STREET DRIA, VA 22314		ART UNIT	PAPER NUMBER
	,	1635		
		DATE MAILED: 06/28/2006		

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)	
		09/937,057	CARPENTIER, A	NTOINE F
Office Action Sui	mmary	Examiner	Art Unit	
		Jane Zara	1635	
The MAILING DATE of the Period for Reply	his communication app	ears on the cover shee	t with the correspondence ac	ddress
A SHORTENED STATUTORY WHICHEVER IS LONGER, FR - Extensions of time may be available und after SIX (6) MONTHS from the mailing of - If NO period for reply is specified above, - Failure to reply within the set or extended Any reply received by the Office later that earned patent term adjustment. See 37	ROM THE MAILING DA er the provisions of 37 CFR 1.13 late of this communication. the maximum statutory period w diperiod for reply will, by statute, in three months after the mailing	ATE OF THIS COMMU 16(a). In no event, however, ma rill apply and will expire SIX (6) cause the application to become	JNICATION. By a reply be timely filed MONTHS from the mailing date of this one ABANDONED (35 U.S.C. § 133).	
Status				
 Responsive to communication This action is FINAL. Since this application is included in accordance with 	2b)⊠ This n condition for allowar	action is non-final.	natters, prosecution as to the C.D. 11, 453 O.G. 213.	e merits is
Disposition of Claims				
	is/are withdravelowed. is/are rejected. is/are objected. is/are: a) accellowed.	vn from consideration. I to. relection requirement. r. repted or b) □ objected drawing(s) be held in abeon is required if the draw	to by the Examiner. eyance. See 37 CFR 1.85(a). ving(s) is objected to. See 37 C	• •
Priority under 35 U.S.C. § 119				
12) △ Acknowledgment is made a) △ All b) □ Some * c) □ 1. △ Certified copies of 2. □ Certified copies of 3. □ Copies of the certi	None of: the priority documents the priority documents fied copies of the prior e International Bureau	s have been received. s have been received i ity documents have be (PCT Rule 17.2(a)).	n Application No een received in this National	Stage
Attachment(s) 1) Notice of References Cited (PTO-89: 2) Notice of Draftsperson's Patent Draw 3) Information Disclosure Statement(s) Paper No(s)/Mail Date	ing Review (PTO-948)	Paper	ew Summary (PTO-413) No(s)/Mail Date of Informal Patent Application (PTO	O-152)

Application/Control Number: 09/937,057

Art Unit: 1635

DETAILED ACTION

This Office action is in response to the communication filed 5-16-06.

Claims 52-66 are pending in the instant application.

Withdrawn Rejections

Any rejections not repeated in this Office action are hereby withdrawn.

New Rejections

Claim Rejections - 35 USC § 102

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 52, 53, 56 and 63 are rejected under 35 U.S.C. 102(e) as being anticipated by Creasy et al (USPN 6,165,766).

Creasy et al teach antitumor compositions comprising a nucleic acid sequence comprising the immunostimulatory oligonucleotide sequence AACGTTAT, which nucleic acid is optionally single stranded or double stranded, and which compositions further comprising an encapsulating agent, colloidal dispersion system or polymer (see SEQ ID NO. 1 of '766, esp. at nucleotides 950-960; see also col. 7, line 58-col. 9, line 12; col. 12, line 26-col. 13, line 14).

Art Unit: 1635

Conclusion

Certain papers related to this application may be submitted to Art Unit 1635 by facsimile transmission. The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 C.F.R., 1.6(d)). The official fax telephone number for the Group is 571-273-8300. NOTE: If Applicant *does* submit a paper by fax, the original signed copy should be retained by applicant or applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to **Jane Zara** whose telephone number is **(571) 272-0765**. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Peter Paras, can be reached on (571) 272-4517. Any inquiry regarding this application should be directed to the patent analyst, Katrina Turner, whose telephone number is (571) 272-0564. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should

Art Unit: 1635

you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free).

Jane Zara 6-19-06

A7 + 1600

JANE ZARA, PH.U. PRIMARY EXAMINER